Raltitrexed
Based on 13 publication(s) in Google Scholar
Raltitrexed is an antimetabolite agent used in chemotherapy, acting by inhibiting thymidylate synthase.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.51%
- No. CAS: 112887-68-0
- Fòrmula: C21H22N4O6S
- Peso molecular:458.49
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Raltitrexed
More- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Nat Commun. 2025 Jul 25;16(1):6880. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Sci Data. 2024 Sep 19;11(1):1024. [Abstract]
- Sci Data. 2022 Oct 8;9(1):610. [Abstract]
- Commun Biol. 2022 Jun 23;5(1):619. [Abstract]
- Int Immunopharmacol. 2024 Nov 15:141:112955. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Cancer Med. 2026 May;15(5):e71898. [Abstract]
- bioRxiv. 2025 Nov 20.
- SSRN. 2022 Nov 21.
- Methods Mol Biol. 2018:1711:351-398. [Abstract]
Customer Validation & Images
-
RT-PCR
-
Histological Imaging/Staining
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
4.68 μM
Compound: RTX
|
Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36331508] |
| A549 | IC50 |
0.81 μM
Compound: RTX
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36331508] |
| HCT-116 | IC50 |
0.076 μM
Compound: RTX
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36331508] |
| HeLa | IC50 |
5.51 μM
Compound: RTX
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36331508] |
| HepG2 | IC50 |
1.3 μM
Compound: Raltitrexed, ZD1694
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 23490159] |
| HepG2 | IC50 |
9.63 μM
Compound: RTX
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36331508] |
| IGROV-1 | IC50 |
12.6 nM
Compound: raltitrexed
|
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells
|
[PMID: 18680275] |
| IGROV-1 | IC50 |
20 nM
Compound: raltitrexed
|
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid
Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid
|
[PMID: 18680275] |
| IGROV-1 | IC50 |
12.6 nM
Compound: RTX, ZD-1694
|
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| IGROV-1 | IC50 |
20 nM
Compound: RTX, ZD-1694
|
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
|
[PMID: 21879757] |
| KB | IC50 |
22 nM
Compound: raltitrexed
|
Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid
Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid
|
[PMID: 18680275] |
| KB | IC50 |
5.9 nM
Compound: raltitrexed
|
Antiproliferative activity against human RFC and FRalpha expressing human KB cells
Antiproliferative activity against human RFC and FRalpha expressing human KB cells
|
[PMID: 18680275] |
| KB | IC50 |
22 nM
Compound: RTX, ZD-1694
|
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid
|
[PMID: 21879757] |
| KB | IC50 |
5.9 nM
Compound: RTX, ZD-1694
|
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| KB | IC50 |
22 nM
Compound: RTX, raltitrexed
|
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid
|
[PMID: 24111942] |
| KB | IC50 |
5.9 nM
Compound: RTX, raltitrexed
|
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay
Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay
|
[PMID: 24111942] |
| KB | IC50 |
22 nM
Compound: RTX
|
Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay
Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay
|
[PMID: 25234128] |
| KB | IC50 |
5.9 nM
Compound: RTX
|
Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
|
[PMID: 25234128] |
| KB | IC50 |
22 nM
Compound: RTX
|
Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs in presence of folic acid by Cell-Titer Blue assay
Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs in presence of folic acid by Cell-Titer Blue assay
|
[PMID: 29425443] |
| KB | IC50 |
5.9 nM
Compound: RTX
|
Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay
Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay
|
[PMID: 29425443] |
| L1210 | IC50 |
0.009 μM
Compound: 1 (Tomudex)
|
Growth inhibition of murine tumor L1210 cell line
Growth inhibition of murine tumor L1210 cell line
|
[PMID: 10508430] |
| L1210 | IC50 |
670 nM
Compound: 1 (Tomudex)
|
Inhibition of isolated thymidylate synthase partially purified from L1210 mouse leukemia cells
Inhibition of isolated thymidylate synthase partially purified from L1210 mouse leukemia cells
|
[PMID: 10508430] |
| L1210 | IC50 |
0.007 μM
Compound: 8a
|
Tested for the concentration to inhibit 50% of L1210 cell growth in culture.
Tested for the concentration to inhibit 50% of L1210 cell growth in culture.
|
[PMID: 2066994] |
| L1210 | IC50 |
0.96 μM
Compound: 8a
|
Compound was tested for the concentration to inhibit 50% of L1210:1565 cell growth.
Compound was tested for the concentration to inhibit 50% of L1210:1565 cell growth.
|
[PMID: 2066994] |
| L1210 (1565) | IC50 |
0.76 μM
Compound: 1 (Tomudex)
|
Inhibition of cell growth in culture against murine tumor L1210:1565 cell lines
Inhibition of cell growth in culture against murine tumor L1210:1565 cell lines
|
[PMID: 10508430] |
| L1210 (RD1694) | IC50 |
95 μM
Compound: 1 (Tomudex)
|
Tested for inhibition of cell growth in culture against murine tumor L1210:RD1694 cell lines
Tested for inhibition of cell growth in culture against murine tumor L1210:RD1694 cell lines
|
[PMID: 10508430] |
| MCF-10A | IC50 |
>20 μM
Compound: RTX
|
Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36331508] |
| MCF7 | IC50 |
12.6 μM
Compound: Raltitrexed, ZD1694
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23490159] |
| MCF7 | IC50 |
10.9 μM
Compound: RTX
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36331508] |
| MDA-MB-231 | IC50 |
>20 μM
Compound: RTX
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36331508] |
| MGC-803 | IC50 |
9.52 μM
Compound: RTX
|
Cytotoxicity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36331508] |
| R2 | IC50 |
>1000 nM
Compound: raltitrexed
|
Antiproliferative activity against human RFC expressing Chinese hamster R2 cells
Antiproliferative activity against human RFC expressing Chinese hamster R2 cells
|
[PMID: 18680275] |
| R2 | IC50 |
99.5 nM
Compound: RTX, ZD-1694
|
Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| R2 | IC50 |
>1000 nM
Compound: RTX, ZD-1694
|
Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs
Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs
|
[PMID: 21879757] |
| R2 | IC50 |
99.5 nM
Compound: RTX, raltitrexed
|
Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay
Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay
|
[PMID: 24111942] |
| R2 | IC50 |
99.5 nM
Compound: RTX
|
Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay
Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay
|
[PMID: 24256410] |
| R2 | IC50 |
>1000 nM
Compound: RTX
|
Cytotoxicity against Chinese hamster R2 cells expressing empty vector assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
Cytotoxicity against Chinese hamster R2 cells expressing empty vector assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
|
[PMID: 25234128] |
| R2 | IC50 |
>1000 nM
Compound: RTX
|
Cytotoxicity against Chinese hamster R2 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
Cytotoxicity against Chinese hamster R2 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay
|
[PMID: 25234128] |
| R2 | IC50 |
15 nM
Compound: RTX
|
Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue fluorescence analysis
Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue fluorescence analysis
|
[PMID: 27458733] |
| R2 | IC50 |
15 nM
Compound: RTX
|
Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay
Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay
|
[PMID: 29425443] |
| SGC-7901 | IC50 |
8.7 μM
Compound: Raltitrexed, ZD1694
|
Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
|
[PMID: 23490159] |
| U2OS | IC50 |
>20 μM
Compound: RTX
|
Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 36331508] |
Raltitrexed inhibits HepG2 proliferation by arresting the cell cycle at G0/G1, and the cell cycle is mediated via downregulation of cyclin A and CDK2[1]. Raltitrexed (0.1, 0.5, 2.5 μg/mL) decreases the viability of SGC7901 cells in a dose- and time-dependent manner. Raltitrexed (0.5 μg/mL) shows typical apoptotic morphology, including nuclear shrinkage, fragmentation, chromatin condensation and apoptotic bodies in SGC7901 cells. Raltitrexed blocks the cell cycle at the G0/G1 phase, decreases in the mitochondrial membrane potential. Raltitrexed also increases the level of ROS, induces caspase-3-dependent apoptosis via activation of the mitochondria, and increases TS protein and mRNA expression levels[3]. Raltitrexed (1.5 nM) reduces the number of GM00637 cells, selectively induces gene conversions, but does not affect DSB-induced HR or NHEJ[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 112887-68-0
-
Appearance Solid
-
Peso molecular 458.49
-
Fòrmula C21H22N4O6S
-
Color Off-white to yellow
-
SMILES
CC(NC1=O)=NC2=C1C=C(CN(C)C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)S3)C=C2
-
Synonyms
ZD1694; D1694; ICI-D1694
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
Nat Commun
The RNA-binding protein RRP1 brakes macrophage one-carbon metabolism to suppress autoinflammation. [Abstract]2025 Jul 25;16(1):6880. PMID: 40715096
Raltitrexed purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 25;16(1):6880. [Abstract]
RT-qPCR detection of IL-1β and IL-6 mRNA levels in RRP1 KO RAW 264.7 cells pre-treated with Raltitrexed in the indicated concentrations and IL-1β stimulation for the indicated hours.
Raltitrexed purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 25;16(1):6880. [Abstract]
H&E staining of the carpal joints or knee joints of Rrp1fl/fl Csflr-IRES-Cre+ mice treated with Raltitrexed (10 mg/kg, i.p.) (right) and the vehicle-treated control littermates (left) on day13.
-
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Sci Data
High-content, arrayed compound screens with rhinovirus, influenza A virus and herpes simplex virus infections. [Abstract]2022 Oct 8;9(1):610. PMID: 36209289 -
Commun Biol
Serine hydroxymethyltransferase as a potential target of antibacterial agents acting synergistically with one-carbon metabolism-related inhibitors. [Abstract]2022 Jun 23;5(1):619. PMID: 35739195 -
Int Immunopharmacol
Capecitabine mitigates cardiac allograft rejection via inhibition of TYMS-Mediated Th1 differentiation in mice. [Abstract]2024 Nov 15:141:112955. PMID: 39163685 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Cancer Med
Metronomic Capecitabine Triggers Ferroptosis in Hepatocellular Carcinoma Cells Through Inhibition of TYMS. [Abstract]2026 May;15(5):e71898. PMID: 42108395 -
-
-
Methods Mol Biol
2018:1711:351-398. PMID: 29344898
Solvente y solubilidad
DMSO : ≥ 29 mg/mL (63.25 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
To assess the effect of Raltitrexed on cell viability and/or growth, GM00637 cells are plated into 25 cm2 flasks at a density of 3.3×105 cells per flask. Twenty four hours later, the medium is replaced with medium supplemented with various doses of Raltitrexed over a broad range of concentrations ranging from less than 1 nM to greater than 1 µM. Three flasks of cells are used for each dose tested. Cells are exposed to Raltitrexed for 24 hours, at which time the cells are refed with medium containing no Raltitrexed. Forty-eight hours after feeding with drug-free medium, cells are harvested and counted. The cell counts for the cells exposed to the various Raltitrexed doses are compared with the cell count for control cells not exposed to Raltitrexed as a measure of the impact of Raltitrexed on cell viability and/or growth rate.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The adult (7-8 week, 19-20 g) C57BL/6 mice are used in the experiment. Mice are maintained under 22°C with a 12 h light/day cycle and fed with standard mouse chow and tap water ad libitum. Female mice are mated with male overnight and vaginal plugs are examined in the following morning. The presence of vaginal plug in the pregnant mice is considered as gestational day 0.5. Pregnant mice are randomly divided into 6 groups with 10 mice in each group. Raltitrexed is dissolved in 0.9 % NaCl, and five groups are intraperitoneally injected with different doses of Raltitrexed (5, 10, 11.5, 13.5, 15 mg/kg b/w) on gestational day 7.5. The control group is intraperitoneally injected with 0.9 % NaCl at the same volume on gestational day 7.5. On gestational day 11.5, pregnant mice are sacrificed, and embryos are examined under dissect microscope.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (643 KB)
- English - EN (643 KB)
- Français - FR (643 KB)
- Deutsch - DE (643 KB)
- Norwegian - NO (643 KB)
- Español - ES (643 KB)
- Swedish - SV (643 KB)
- Italian - IT (643 KB)
- Korean - KR (643 KB)
- Portuguese - PT (643 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Zhao H, et al. Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest. Oncol Res. 2016;23(5):237-48 [Content Brief]
[2]. Dong Y, et al. Raltitrexed's effect on the development of neural tube defects in mice is associated with DNA damage, apoptosis, and proliferation. Mol Cell Biochem. 2015 Jan;398(1-2):223-31. [Content Brief]
[3]. Xue S, et al. Raltitrexed induces mitochondrial-mediated apoptosis in SGC7901 human gastric cancer cells. Mol Med Rep. 2014 Oct;10(4):1927-34. [Content Brief]
[4]. Waldman BC, et al. Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase. DNA Repair (Amst). 2008 Oct 1;7(10):1624-35. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1811 mL | 10.9054 mL | 21.8107 mL | 54.5268 mL |
| 5 mM | 0.4362 mL | 2.1811 mL | 4.3621 mL | 10.9054 mL | |
| 10 mM | 0.2181 mL | 1.0905 mL | 2.1811 mL | 5.4527 mL | |
| 15 mM | 0.1454 mL | 0.7270 mL | 1.4540 mL | 3.6351 mL | |
| 20 mM | 0.1091 mL | 0.5453 mL | 1.0905 mL | 2.7263 mL | |
| 25 mM | 0.0872 mL | 0.4362 mL | 0.8724 mL | 2.1811 mL | |
| 30 mM | 0.0727 mL | 0.3635 mL | 0.7270 mL | 1.8176 mL | |
| 40 mM | 0.0545 mL | 0.2726 mL | 0.5453 mL | 1.3632 mL | |
| 50 mM | 0.0436 mL | 0.2181 mL | 0.4362 mL | 1.0905 mL | |
| 60 mM | 0.0364 mL | 0.1818 mL | 0.3635 mL | 0.9088 mL |
Raltitrexed Related Classifications
HY-10821 Related Classifications
Powered by Bioz